Dyne Therapeutics, Inc. Income Statement
DYN / Health Care|6 years of annual SEC 10-K data (FY2019-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| SG&A Expense | $62.5M | $31.4M | $28.2M | $28.7M | $13.4M | $2.8M |
| R&D Expense | $281.4M | $210.8M | $142.8M | $121.3M | $45.2M | $11.0M |
| Operating Income | -$343.9M | -$242.2M | -$171.0M | -$150.0M | -$58.6M | -$13.8M |
| Net Income | -$317.4M | -$235.9M | -$168.1M | -$149.3M | -$59.4M | -$14.9M |
| EPS (Basic) | -$3.37 | -$3.95 | -$3.23 | -$2.93 | - | - |
| EPS (Diluted) | -$3.37 | -$3.95 | -$3.23 | -$2.93 | - | - |
| Shares Outstanding | 102.3M | 61.5M | 55.6M | 50.9M | 14.4M | 2.4M |